lung cancer

Pfizer's Lorbrena makes play for earlier lung cancer use with Xalkori-topping data
Pfizer's Lorbrena makes play for earlier lung cancer use with Xalkori-topping data
Fierce Pharma
Pfizer
Lorbrena
lung cancer
Xalkori
clinical trials
Flag link:
A turn-up for Spectrum’s book
A turn-up for Spectrum’s book
EP Vantage
poziotinib
Spectrum Pharmaceuticals
lung cancer
Takeda
Flag link:
Lung cancer study IDs new 'epigenomic' target for diagnosis and treatment
Lung cancer study IDs new 'epigenomic' target for diagnosis and treatment
Fierce Biotech
Harvard
MIT
epigenomics
cancer
lung cancer
diagnostics
Flag link:
In pilot of patient-reported outcomes project, FDA hopes to encourage ‘more rigorous’ data collection
In pilot of patient-reported outcomes project, FDA hopes to encourage ‘more rigorous’ data collection
MedCity News
AstraZeneca
clinical trials
Tagrisso
FDA
lung cancer
patients
Flag link:
ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancers
ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancers
Pharmaforum
Daiichi Sankyo
AstraZeneca
Enhertu
stomach cancer
colorectal cancer
lung cancer
ASCO 2020
Flag link:
AstraZeneca's Blockbuster Lung Cancer Drug Has a Huge Sales Boost Ahead
AstraZeneca's Blockbuster Lung Cancer Drug Has a Huge Sales Boost Ahead
Motley Fool
AstraZeneca
ASCO 2020
lung cancer
adjuvants
Tagrisso
Flag link:
AstraZeneca bid to expand lung cancer drug's use boosted by trial data
AstraZeneca bid to expand lung cancer drug's use boosted by trial data
BioPharma Dive
AstraZeneca
Tagrisso
lung cancer
clinical trials
ASCO 2020
Flag link:
3 Roche Companies Hope to Make Clinical Trials More Efficient
3 Roche Companies Hope to Make Clinical Trials More Efficient
Medical Devices and Diagnostics Industry
Flatiron Health
Foundation Medicine
Genentech
Roche
genomics
clinical trials
lung cancer
Flag link:
AstraZeneca to unveil key data for cancer drugs at ASCO
AstraZeneca to unveil key data for cancer drugs at ASCO
Pharmaforum
AstraZeneca
ASCO 2020
Tagrisso
lung cancer
Enhertu
breast cancer
gastric cancer
colorectal cancer
Flag link:
ASCO 2020 – first-line lung cancer focus
ASCO 2020 – first-line lung cancer focus
EP Vantage
Roche
Merck
Bristol-Myers Squibb
ASCO 2020
lung cancer
Keytruda
tiragolumab
Opdivo
Yervoy
Flag link:
Go or no go? Oncology dominates upcoming decisions
Go or no go? Oncology dominates upcoming decisions
EP Vantage
FDA
oncology
AstraZeneca
Lynparza
ovarian cancer
prostate cancer
Bristol-Myers Squibb
Opdivo
lung cancer
Flag link:
#AACR20: Early data suggest Novartis' Incyte-discovered MET inhibitor helps lung cancer patients with brain lesions
#AACR20: Early data suggest Novartis' Incyte-discovered MET inhibitor helps lung cancer patients with brain lesions
Endpoints
Novartis
Incyte
AACR
lung cancer
MET inhibitors
capmatinib
Flag link:
Lantern files for IPO to study 5-time phase 3 cancer failure
Lantern files for IPO to study 5-time phase 3 cancer failure
Fierce Biotech
Lantern Pharma
IPOs
LP-300
lung cancer
Flag link:
BeiGene reports positive Phase III interim analysis for lung cancer drug
BeiGene reports positive Phase III interim analysis for lung cancer drug
MedCity News
BeiGene
clinical trials
immunotherapy
lung cancer
tislelizumab
non-squamous non-small cell lung cancer
Flag link:
AstraZeneca's Imfinzi gets FDA nod to target small-cell lung cancer
AstraZeneca's Imfinzi gets FDA nod to target small-cell lung cancer
Reuters
AstraZeneca
FDA
Imfinzi
lung cancer
Small-Cell Lung Cancer
Flag link:
First of its Kind “Universal” Immune Cell Cancer Therapy
First of its Kind “Universal” Immune Cell Cancer Therapy
Xtalks
cancer
immune system
prostate cancer
lung cancer
breast cancer
Cardiff University
Flag link:
BeiGene lung cancer treatment meets main goal in late-stage study
BeiGene lung cancer treatment meets main goal in late-stage study
Reuters
BeiGene
cancer
lung cancer
clinical trials
tislelizumab
Flag link:
The three biggest challenges in lung cancer, and how researchers are tackling them
The three biggest challenges in lung cancer, and how researchers are tackling them
Pharmaforum
lung cancer
Lung Ambition Alliance
R&D
Flag link:
Bankrupt uBiome sells off patents, data for $7M; J&J buys options on Pulmatrix's lung cancer drugs
Bankrupt uBiome sells off patents, data for $7M; J&J buys options on Pulmatrix's lung cancer drugs
Endpoints
uBiome
microbiome
M&A
Psomagen
JNJ
Pulmatrix
lung cancer
Flag link:
Spectrum Pharma Shares Slump After Lung-Cancer Drug Doesn't Meet Phase II Endpoint
Spectrum Pharma Shares Slump After Lung-Cancer Drug Doesn't Meet Phase II Endpoint
TheStreet.com
Spectrum Pharma
lung cancer
clinical trials
poziotinib
non-small cell lung cancer
Flag link:

Pages